Nuvectis Pharma (NVCT) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Aug 24, 2026 |
| Roth Capital | Maintained | Buy | $33.00 from $20.00 | Jul 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $39.00 from $13.00 | Jun 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $10.00 | Jun 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $15.00 | Aug 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $15.00 from $11.00 | Apr 30, 2025 |
| Maxim Group | Initiated Coverage | Buy | $17.00 | Apr 2, 2025 |
| Laidlaw & Co. | Initiated Coverage | Buy | $19.00 | Mar 17, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $11.00 from $21.00 | Feb 25, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Aug 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | May 8, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $21.00 | Sep 15, 2023 |
Frequently asked questions
Is NVCT a buy, sell, or hold?
Analysts covering Nuvectis Pharma currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NVCT?
On Aug 24, 2026, Cantor Fitzgerald initiated coverage of Nuvectis Pharma at Overweight.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.